No description available.

Introduktion: På senare tid har en ny generation av antikoagulantia (NOAK) uppkommit. NOAK kommer med fördelar då tidigare antikoagulantia behandling krävt täta läkarkontroller, reglering av dosering och hänsyn till kost. Tidigare antikoagulantia som warafarin och hepariner inhiberar flera koagulationsfaktorer. Medan Edoxaban som tillhör NOAK endast hämmar fria faktor Xa och protrombinaktivitet. Som följd av detta har Edoxaban en bättre effekt och ger ett mer säkert resultat vid korrekt ordination. Eftersom Edoxaban elimineras via njurar är det viktigt med njurfunktionskontroller som görs via estimerat glomerulär filtrationshastighet (eGFR). Kreatininbaserad eGFR gjordes med Lund-Malmö-formeln (LM) som är anpassad för den svenska populationen. Cystatin-C-baserad eGFR beräknas via Caucasian-Asian-pediatric-and-adult-cohorts-formeln (CAPA) där endast ålder tas hänsyn, till skillnad från LM-formeln där fler faktorer spelar roll. Syftet: Undersöka korrelationen mellan kreatininbaserade eGFR formeln LM och cystatin-C-baserad eGFR formeln CAPA. Metod: Blodprov togs från 43 Edoxabanbehandlade patienter i Karlstad Centralsjukhus. Patienternas eGFR beräknades via CAPA- respektive LM-formel. Faktorer som vikt, längd och ålder togs till hänsyn. Resultat: LM- och CAPA-eGFR visar en stark korrelation. Slutsats: LM-eGFR påverkas av fler faktorer och som följd fungerar bäst för patienter med balanserad längd och vikt samt stabil kost. Medan CAPA-eGFR, som påverkas av färre faktorer är anpassade för patienter som är över- och underviktiga med mycket varierad kost. / Introduction: A new generation of anticouagulants has emerged called NOAC. NOAC comes with benefits that have previously been problematic for patients treated with anticouagulants such as regular check-ups and dose regulation. Previous anticouagulants, warafarin and heparins, inhibits multiple coagulation factors. While NOAC only inhibits select few factors. For example, Edoxaban only inhibits free factor Xa and prothrombin activity. As result, Edoxaban has a better effect with proper prescription. Edoxaban eliminates through the kidneys which makes renal function tests important – eGFR. Creatinine-based eGFR is calculated via LM-formula which is adapted for the Swedish population. Cystatin-C-based eGFR is calculated via CAPA formula where only age is taken into account whereas the LM-formula relies on multiple factors. Aim: The purpose of the study is to understand the correlation between creatinine- and cystatin-C-based eGFR. Method: blood samples were taken from 43 patient treated with Edoxaban at Karlstad Hospital. eGFR were calculated via CAPA and LM formula. Weight, age and height were taken into account.  Result: A strong correlation shows in LM- and CAPA-eGFR. Conclusion: LM-eGFR is affected by several factors therefore works best for patients with balanced height and weight as well as a stable diet. Patients who are overweight, underweight or has a very varied diet is best fit for CAPA-eGFR which is unaffected by these factors.

Bakgrund: För estimering av glomerulär filtrationshastighet (eGFR) behövs ett blodprov, såsom kreatinin eller cystatin C. En av röntgensjuksköterskans arbetsuppgifter är skattning av GFR innan jodkontrastmedel administreras, på grund av risken för njurbiverkningar. Hos äldre patienter är känsligheten för läkemedel påtaglig på grund av förändrad farmakokinetik. Osäkerhet råder om vilket blodprov som ger noggrannast eGFR.  Syfte: Syftet med studien var att genom litteraturgenomgång undersöka hur markörerna kreatinin respektive cystatin C skattar eGFR hos äldre patienter. Metod: Syftet besvarades av en litteraturstudie med resultat från åtta kvantitativa studier. De ingående studierna analyserades och sammanställdes. Databassökningarna utfördes i PubMed och Cinahl. Resultat: Resultatet visade att skattningarna av eGFR kunde skilja sig signifikant mellan kreatinin och cystatin C, medan andra gånger var de mer liknande. Vid stigande ålder ökade skillnaden mellan skattningarna av eGFR med de två markörerna. Konklusion:  Varken kreatinin eller cystatin C är optimalt. Delar av resultatet pekade mot att kombinationen kan vara en fördel. Mer forskning behövs inom området. / Background: When estimating glomerular filtration rate (eGFR), a blood test is required, such as creatinine or cystatin C. One of the radiographers' assignments is to estimate GFR before administering iodinated contrast agents, due to the risk of renal side effects. In elderly patients, the sensitivity to drugs is palpable due to altered pharmacokinetics. There is uncertainty about which blood test produces the most accurate eGFR. Aim: The aim was to investigate through a literature review how the markers creatinine and cystatin C estimate eGFR in elderly patients. Methods: The aim was answered by a literature study with results from eight quantitative studies, that were found in the databases PubMed and Cinahl. All included studies were analyzed and compiled. Results: The results showed that the estimates of eGFR could differ significantly between creatinine and cystatin C, while other times they were more similar. With an increasing age the two markers showed a larger difference in estimation of GFR. Conclusion: Neither creatinine nor cystatin C is optimal. Parts of the results indicated that the combination may be an advantage. More research is needed in this area.

Inledning: Undersökningar som inkluderar kontrastmedel har ökat på datortomografin (DT). Inför kontrastmedelsundersökningar ska den glomerulära filtrationshastigheten (GFR) estimeras för att få ett mått på patientens njurfunktion. I nuläget finns det två olika markörer som kan användas till detta, kreatinin och cystatin C. Det är röntgensjuksköterskans ansvar att skatta GFR för att kunna göra en bedömning om patienten kan utföra undersökningen. Syfte: Syftet med studien var att sammanställa studier som jämför kreatinin och cystatin C vid skattning av GFR. Metod: Den här studien genomfördes som en allmän litteraturöversikt. Litteratursökningen genomfördes i databaserna CINAHL, PubMed och SveMed+. Tio kvantitativa vetenskapliga artiklar lokaliserades och gick vidare till analys. Resultat: Resultatet visade att cystatin C i många fall var en bättre indikator för att estimera GFR. Slutsats: För äldre och njursjuka ansågs cystatin C vara en bättre markör för njurfunktionen. Dock anser författarna att det krävs vidare forskning inom ämnet och dess påverkande faktorer för att kunna introducera cystatin C som ny njurfunktionsmarkör.

No description available.

Os rins desempenham um papel fundamental no sistema urinário e sua principal função é a filtração do sangue. Uma das causas que podem comprometer o funcionamento dos rins é a Insuficiência Renal Aguda (IRA) que é definida como a diminuição da taxa de filtração glomerular (TFG) de forma rápida e inesperada, causando a perda da função renal. Essa doença apresenta um número significativo de internações e também óbitos. O marcador padrão usado nos exames laboratoriais é a creatinina sérica, no entanto, a concentração da creatinina sérica pode variar dependendo de vários fatores, como idade, sexo, nutrição, entre outros. Além disso, sua concentração não varia consideravelmente nas primeiras indicações da lesão renal. Dessa forma, o diagnóstico é tardio e a função renal já pode estar comprometida. A proteína cistatina C (CST3) vem sendo indicada como um novo marcador para a doença, mostrando superioridade especialmente para detectar pequenas variações da TFG. A concentração da cistatina C não varia significativamente com a idade, sexo e massa muscular. Assim, foi desenvolvido um imunossensor para detectar a cistatina C, usando a configuração de transistor de efeito de campo de porta estendida e separada (SEGFET). Os eletrodos foram caracterizados por várias técnicas como MEV, microscopia de força atômica, técnicas eletroquímicas e também foi analisada a sensibilidade do ouro. As etapas de construção do imunossensor, e a interação do anticorpo com concentrações crescentes da proteína foram verificadas através de técnicas eletroquímicas, na faixa de concentração de 3 a 100 ng.mL-1. Nas medidas no SEGFET observou-se uma mudança significativa da corrente após a adição da cistatina C e para as substâncias interferentes não. O imunossensor apresentou alta sensibilidade detectando concentrações bem baixas da proteína alvo. A curva analítica ΔIDS% x [CST3] obteve-se L.D. = 0,75 ng.mL-1, L.Q. = 2,27 ng.mL-1 e r = 0,98122. A curva analítica ΔVGS% x [CST3] obteve-se L.D. = 0,28 ng.mL-1, L.Q. = 0,87 ng.mL-1 e r = 0,99846. Embora tenha algumas limitações o imunossensor é inovador e apresenta muitas vantagens podendo ser aplicado futuramente para o diagnóstico da doença. / The kidneys play a key role in the urinary system and its main function is the filtration of blood. One of the causes that can compromise the functioning of the kidneys is the Acute Kidney Injury (AKI), which is defined as the quickly and unexpected decrease in Glomerular Filtration Rate (GFR), causing the loss of kidney function. This disease presents a significant number of hospitalizations and also deaths. The standard marker used in laboratory tests is serum creatinine, however, serum creatinine concentration may vary depending on a number of factors, such as age, sex, nutrition, and so on. In addition, its concentration does not vary considerably in the first indications of renal injury. Thus, the diagnosis is delayed and renal function may already be compromised. The cystatin C protein (CST3) has been indicated as a new marker for the disease, showing superiority especially for detecting small variations in GFR. The concentration of cystatin C does not vary significantly with age, sex and muscle mass. Thus, an immunosensor was developed to detect cystatin C using the extended and a separate gate field effect transistor (SEGFET) configuration. The electrodes were characterized by several techniques such as SEM, atomic force microscopy, electrochemical techniques and also the sensitivity of gold was analyzed. The construction of the immunosensor, and the interaction of the antibody with increasing concentrations of the protein were verified by electrochemical techniques, in the concentration range of 3 to 100 ng.mL-1. In the measurements in the SEGFET a significant change of the current was observed after the addition of cystatin C and for the interfering substances there was no difference. The immunosensor showed high sensitivity detecting very low concentrations of the target protein. The analytical curve ΔIDS% x [CST3] was obtained L.D. = 0,75 ng.mL-1, L.Q. = 2,27 ng.mL-1 and r = 0,98122. The analytical curve ΔVGS% x [CST3] was obtained L.D. = 0,28 ng.mL-1, L.Q. = 0,87 ng.mL-1 and r = 0,99846. Although it has some limitations the immunosensor is innovative and presents many advantages and can be applied in the future to diagnose the disease.

Cystatin C, a 13 kDa low molecular weight protein is an inhibitor of cysteine proteases. Due to its low molecular weight and positive charge at physiological pH, it is freely filtered by the glomerulus and catabolized after reabsorption by proximal tubular cells with a low concentration (0.03-0.3 mg/L) in urine amongst healthy subjects. Urinary cystatin C is a potential biomarker detection of acute kidney injury (AKI) in the acute phase when patients are submitted to the intensive care unit. The aim in this report was to perform a full method validation of urinary analysis of cystatin C on a high throughput chemical analyzer by particle-enhanced turbidimetric immunoassay (PETIA) at the University Hospital in Uppsala, Sweden. The antigen excess, linearity, lower limit of quantification (LoQ), recovery, assay precision, stability and interference caused by haemoglobin was evaluated. No hook effect was observed, the assay was linear over the studied interval <0.001-0.950 mg/L with a regression of R2=0.9994. The LoQ was calculated to 0.020 mg/L with a coefficient of variation (CV) ≤10% which was considered acceptable. The assay had a recovery between 93-100% and the assay precision had a total CV <3.5%. Cystatin C is stable for 3 days in room temperature and 14 days in +4C. The assay did not show any major interference with haemoglobin. The urinary cystatin C showed good precision and performance characteristics by measurements using PETIA all of which is a necessary qualification for a biomarker at a 24-h running routine laboratory.

As diretrizes nacionais e internacionais de nefrologia e diabetologia recomendam que, em pacientes com diabete melito (DM), além da aferição anual da excreção urinária de albumina, seja realizada a estimativa da TFG por meio de equações que incluam a creatinina sérica. As equações mais empregadas e analisadas têm sido as dos estudos MDRD (Modification of Diet in Renal Disease) e CKD-EPI (Chronic kidney Disease Epidemiology Collaboration). No entanto, algumas evidências demonstram um pior desempenho dessas equações em indivíduos com DM, com acentuada subestimativa da TFG. Este desempenho limitado parece estar relacionado a peculiaridades do paciente com DM, como a presença de hiperglicemia e hiperfiltração glomerular, mas também a limitações da própria creatinina como marcador pouco sensível e específico da TFG. O uso de novos marcadores endógenos com perfil mais próximo do ideal, como é o caso da cistatina C, tem se mostrado promissor, mas a sua acurácia ainda não foi adequadamente demonstrada no DM. O objetivo desse artigo foi analisar criticamente os métodos disponíveis de medida e de estimativa da TFG em pacientes com DM, enfatizando aspectos peculiares e possíveis interferentes. / The current guidelines of Nephrology and Diabetology recommend that in patients with diabetes mellitus (DM), along with the annual measure of urinary albumin excretion, the glomerular filtration rate (GFR) should be estimated using creatinine-based equations. The most frequently recommended equations were developed by the MDRD (Modification of Diet in Renal Disease) and CKDEPI (Chronic Kidney Disease Epidemiology Collaboration) studies. However, recent evidences show a worse performance of these equations in diabetic patients, with a significant underestimation of GFR. This limited performance seems to be related to the peculiarities of the patient with DM, such as the presence of hyperglycemia and glomerular hyperfiltration, but also due to the limitations in the sensitivity and specificity of serum creatinine as GFR marker. The use of new markers with closer–to-the ideal endogenous profile, like cystatin C, has shown promise, but its accuracy has not been yet adequately demonstrated in DM. The purpose of this article was to critically analyze the current available methods of measurement and estimation of GFR in patients with DM, emphasizing its peculiarities and possible interferences.

As diretrizes nacionais e internacionais de nefrologia e diabetologia recomendam que, em pacientes com diabete melito (DM), além da aferição anual da excreção urinária de albumina, seja realizada a estimativa da TFG por meio de equações que incluam a creatinina sérica. As equações mais empregadas e analisadas têm sido as dos estudos MDRD (Modification of Diet in Renal Disease) e CKD-EPI (Chronic kidney Disease Epidemiology Collaboration). No entanto, algumas evidências demonstram um pior desempenho dessas equações em indivíduos com DM, com acentuada subestimativa da TFG. Este desempenho limitado parece estar relacionado a peculiaridades do paciente com DM, como a presença de hiperglicemia e hiperfiltração glomerular, mas também a limitações da própria creatinina como marcador pouco sensível e específico da TFG. O uso de novos marcadores endógenos com perfil mais próximo do ideal, como é o caso da cistatina C, tem se mostrado promissor, mas a sua acurácia ainda não foi adequadamente demonstrada no DM. O objetivo desse artigo foi analisar criticamente os métodos disponíveis de medida e de estimativa da TFG em pacientes com DM, enfatizando aspectos peculiares e possíveis interferentes. / The current guidelines of Nephrology and Diabetology recommend that in patients with diabetes mellitus (DM), along with the annual measure of urinary albumin excretion, the glomerular filtration rate (GFR) should be estimated using creatinine-based equations. The most frequently recommended equations were developed by the MDRD (Modification of Diet in Renal Disease) and CKDEPI (Chronic Kidney Disease Epidemiology Collaboration) studies. However, recent evidences show a worse performance of these equations in diabetic patients, with a significant underestimation of GFR. This limited performance seems to be related to the peculiarities of the patient with DM, such as the presence of hyperglycemia and glomerular hyperfiltration, but also due to the limitations in the sensitivity and specificity of serum creatinine as GFR marker. The use of new markers with closer–to-the ideal endogenous profile, like cystatin C, has shown promise, but its accuracy has not been yet adequately demonstrated in DM. The purpose of this article was to critically analyze the current available methods of measurement and estimation of GFR in patients with DM, emphasizing its peculiarities and possible interferences.

As diretrizes nacionais e internacionais de nefrologia e diabetologia recomendam que, em pacientes com diabete melito (DM), além da aferição anual da excreção urinária de albumina, seja realizada a estimativa da TFG por meio de equações que incluam a creatinina sérica. As equações mais empregadas e analisadas têm sido as dos estudos MDRD (Modification of Diet in Renal Disease) e CKD-EPI (Chronic kidney Disease Epidemiology Collaboration). No entanto, algumas evidências demonstram um pior desempenho dessas equações em indivíduos com DM, com acentuada subestimativa da TFG. Este desempenho limitado parece estar relacionado a peculiaridades do paciente com DM, como a presença de hiperglicemia e hiperfiltração glomerular, mas também a limitações da própria creatinina como marcador pouco sensível e específico da TFG. O uso de novos marcadores endógenos com perfil mais próximo do ideal, como é o caso da cistatina C, tem se mostrado promissor, mas a sua acurácia ainda não foi adequadamente demonstrada no DM. O objetivo desse artigo foi analisar criticamente os métodos disponíveis de medida e de estimativa da TFG em pacientes com DM, enfatizando aspectos peculiares e possíveis interferentes. / The current guidelines of Nephrology and Diabetology recommend that in patients with diabetes mellitus (DM), along with the annual measure of urinary albumin excretion, the glomerular filtration rate (GFR) should be estimated using creatinine-based equations. The most frequently recommended equations were developed by the MDRD (Modification of Diet in Renal Disease) and CKDEPI (Chronic Kidney Disease Epidemiology Collaboration) studies. However, recent evidences show a worse performance of these equations in diabetic patients, with a significant underestimation of GFR. This limited performance seems to be related to the peculiarities of the patient with DM, such as the presence of hyperglycemia and glomerular hyperfiltration, but also due to the limitations in the sensitivity and specificity of serum creatinine as GFR marker. The use of new markers with closer–to-the ideal endogenous profile, like cystatin C, has shown promise, but its accuracy has not been yet adequately demonstrated in DM. The purpose of this article was to critically analyze the current available methods of measurement and estimation of GFR in patients with DM, emphasizing its peculiarities and possible interferences.